These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 18417741

  • 1. Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis.
    McGowan T, Vaccaro NM, Beaver JS, Massarella J, Wolfson M.
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1006-14. PubMed ID: 18417741
    [Abstract] [Full Text] [Related]

  • 2. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease.
    Spinowitz B, Germain M, Benz R, Wolfson M, McGowan T, Tang KL, Kamin M, Epoetin Alfa Extended Dosing Study Group.
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1015-21. PubMed ID: 18400964
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly.
    Cheung W, Minton N, Gunawardena K.
    Eur J Clin Pharmacol; 2001 Aug; 57(5):411-8. PubMed ID: 11599659
    [Abstract] [Full Text] [Related]

  • 4. A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia.
    Pergola PE, Gartenberg G, Fu M, Wolfson M, Rao S, Bowers P.
    Clin J Am Soc Nephrol; 2009 Nov; 4(11):1731-40. PubMed ID: 19808215
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U, PROTOS Study Investigators.
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [Abstract] [Full Text] [Related]

  • 8. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
    Provenzano R, Bhaduri S, Singh AK, PROMPT Study Group.
    Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss.
    Arroliga AC, Guntupalli KK, Beaver JS, Langholff W, Marino K, Kelly K.
    Crit Care Med; 2009 Apr; 37(4):1299-307. PubMed ID: 19242343
    [Abstract] [Full Text] [Related]

  • 10. A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia.
    Pergola PE, Gartenberg G, Fu M, Sun S, Wolfson M, Bowers P.
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):598-606. PubMed ID: 20185602
    [Abstract] [Full Text] [Related]

  • 11. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease.
    Benz R, Schmidt R, Kelly K, Wolfson M.
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):215-21. PubMed ID: 17699416
    [Abstract] [Full Text] [Related]

  • 12. Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease.
    Provenzano R, Singh AK.
    Endocr Pract; 2007 Mar; 13(3):251-9. PubMed ID: 17599856
    [Abstract] [Full Text] [Related]

  • 13. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease.
    Provenzano R, Garcia-Mayol L, Suchinda P, Von Hartitzsch B, Woollen SB, Zabaneh R, Fink JC, POWER Study Group.
    Clin Nephrol; 2004 Jun; 61(6):392-405. PubMed ID: 15224803
    [Abstract] [Full Text] [Related]

  • 14. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.
    Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH.
    J Clin Oncol; 2001 Jun 01; 19(11):2875-82. PubMed ID: 11387360
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
    Fischbach M, Wühl E, Reigner SCM, Morgan Z, Schaefer F.
    Clin J Am Soc Nephrol; 2018 Jan 06; 13(1):81-90. PubMed ID: 29097481
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy.
    Cortesi E, Mancuso A, De Pasquale Ceratti A, Pizzardi N, D'Auria G, Accettura C, Beccaglia P, Bertelletti D, De Marinis F.
    Oncologist; 2004 Jan 06; 9(4):459-68. PubMed ID: 15266099
    [Abstract] [Full Text] [Related]

  • 18. Once-weekly epoetin alfa dosing is as effective as three times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic HIV-infected patients.
    Grossman HA, Goon B, Bowers P, Leitz G, 010 Study Group.
    J Acquir Immune Defic Syndr; 2003 Dec 01; 34(4):368-78. PubMed ID: 14615654
    [Abstract] [Full Text] [Related]

  • 19. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients.
    Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, Bradbury BD.
    Clin J Am Soc Nephrol; 2008 Jul 01; 3(4):1077-83. PubMed ID: 18417744
    [Abstract] [Full Text] [Related]

  • 20. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
    Nurko S, Spirko R, Law A, Dennis VW.
    Clin Ther; 2007 Sep 01; 29(9):2010-21. PubMed ID: 18035200
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.